The study found that AVN944 significantly inhibited the IMPDH enzyme and induced biomarkers associated with cancer cell death. The gene HspA1A marker was elevated even at low doses of the drug, indicating potential for tumor cell apoptosis.
In a Phase III study, eculizumab provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria. Eculizumab therapy also reduced adverse events and showed significant benefits in patient-reported outcomes.
Abstracts on Soliris (eculizumab) will be presented at the ASH Annual Meeting, highlighting its potential to reduce thrombosis in paroxysmal nocturnal hemoglobinuria (PNH) patients. The therapy has shown promise in clinical trials with significant reductions in anemia and intravascular hemolysis.
A Phase III efficacy study led by Dr. Peter Hillmen found eculizumab significantly improves anaemia and quality of life in patients with paroxysmal nocturnal haemoglobinuria (PNH). The treatment also reduces intravascular hemolysis, fatigue, pain, and shortness of breath.
A new pet food, Prescription Diet Canine j/d TM, improves dogs' quality of life by enhancing joint health. With a unique formula containing EPA, glucosamine, and L-carnitine, this food helps dogs run better, play better, and experience less stiffness.
NexMed's Femprox treatment showed demonstrable improvement in sexual arousal, with statistically significant gains reported at the end of both evaluation periods. The study involved 372 patients and found positive patient satisfaction, with side effects being mostly mild and reversible.
Researchers at PTC Therapeutics have discovered a new biochemical pathway that controls cell growth modulation. This finding has significant implications for the development of therapeutics targeting cancer cells, which rely on deregulated translation to grow uncontrollably.
Researchers have demonstrated that adipose-derived cells can engraft and differentiate into cardiac myocytes, offering new hope for treating heart disease. The study's findings are consistent with previous research and are being further explored by MacroPore Biosurgery.
A cholesterol-free mouse model was generated, supporting the 'sterol synergism' theory and highlighting the importance of cholesterol in developmental stages. The knock-out pups showed poorer growth characteristics than normal animals.